Navigation Links
Arena Pharmaceuticals Announces Third Quarter 2009 Financial Results and Recent Developments
Date:11/9/2009

itional $20.0 million under similar terms, with the additional loan also maturing in June 2013. For each additional $1.0 million in funding, Arena will issue Deerfield additional warrants for 280,000 shares of its common stock at an exercise price of $5.42 per share. Arena repaid Deerfield the first scheduled principal repayment of $10.0 million upon completion of its public offering in July.

Scheduled Earnings Call

Arena will host both a conference call and webcast to discuss the third quarter 2009 financial results and to provide a business and financial update tomorrow, Tuesday, November 10, 2009, at 8:30 a.m. Eastern Time (5:30 a.m. Pacific Time). Jack Lief, President and Chief Executive Officer, and Robert E. Hoffman, Vice President, Finance and Chief Financial Officer, will host the conference call.

The conference call may be accessed by dialing 888.452.4024 for domestic callers and 719.325.2385 for international callers. Please specify to the operator that you would like to join the "Arena Pharmaceuticals' Third Quarter 2009 Financial Results Call." The conference call will be webcast live under the investor relations section of Arena's website at www.arenapharm.com, and will be archived there for 30 days following the call. Please connect to Arena's website several minutes prior to the start of the broadcast to ensure adequate time for any software download that may be necessary.

Upcoming Corporate Presentations

Arena is planning to present at upcoming investment and industry conferences, including:

  • Piper Jaffray 21st Annual Health Care Conference, December 1-2, 2009, New York, New York
  • 28th Annual J.P. Morgan Healthcare Conference, January 11-14, 2010, San Francisco, California

About Arena Pharmaceuticals

Arena is a clinical-stage biopharmaceutical company focused on dis
'/>"/>

SOURCE Arena Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Arena Pharmaceuticals to Present at Four Upcoming Investor Conferences
2. Arena Pharmaceuticals Announces Positive Phase 2 Clinical Trial Results of APD125 for the Treatment of Insomnia
3. Arena Pharmaceuticals Announces APD668 Initial Clinical Study Results Suggest Glucose-Dependent Insulinotropic Receptors May Improve Glucose Control in Patients With Type 2 Diabetes
4. Arena Pharmaceuticals Announces Positive Phase 1a Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis and Initiates Phase 1b Clinical Trial
5. Arena Pharmaceuticals Initiates Phase 2b Clinical Trial of APD125 for the Treatment of Insomnia
6. Arena Pharmaceuticals, Inc. Announces Initiation of Phase 1 Clinical Trial of Drug Candidate Under Partnership with Taisho Pharmaceutical Co., Ltd.
7. Arena Pharmaceuticals Presented Positive Phase 2a Clinical Trial Results of APD125 for the Treatment of Insomnia at 22nd Annual Meeting of the Associated Professional Sleep Societies
8. Arena Pharmaceuticals Announces Positive Phase 1b Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis
9. Critical Pharmaceuticals Enter Sustained Release hGH Arena
10. Arena Pharmaceuticals Announces Preliminary Results of Phase 2b Clinical Trial of APD125 for the Treatment of Insomnia
11. Arena Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of Type 2 Diabetes Drug Candidate in Partnership with Ortho-McNeil-Janssen Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... Mass. , March 27, 2015 ... platform for drug discovery and development services which ... for the pharmaceutical industry, announced financial results for ... Timothy C.  Tyson, Chairman of XRpro Sciences ... to successfully transition from development stage to commercial ...
(Date:3/27/2015)... March 27, 2015  Valeant Pharmaceuticals International, Inc. (NYSE: ... of its previously announced registered offering of common shares ... "Offering"). Pursuant to the Offering, the Company issued 7,286,432 ... for aggregate gross proceeds of approximately $1.45 billion. On ... Securities and Exchange Commission a final prospectus supplement to ...
(Date:3/27/2015)... , March 27, 2015 The International ... of myeloma patients while working toward prevention and a ... (D-NY) for introducing a federal resolution (H. Res. 174) ... 2015 as "National Multiple Myeloma Awareness Month." ... myeloma worldwide, and more than 110,000 new cases are ...
Breaking Medicine Technology:XRpro Sciences Announces Fiscal 2014 Financial Results 2XRpro Sciences Announces Fiscal 2014 Financial Results 3XRpro Sciences Announces Fiscal 2014 Financial Results 4Valeant Pharmaceuticals Closes Offering Of $1.45 Billion Of Common Shares 2Valeant Pharmaceuticals Closes Offering Of $1.45 Billion Of Common Shares 3The International Myeloma Foundation (IMF) Secures the Introduction of a Federal Resolution Recognizing March 2015 as "National Multiple Myeloma Awareness Month" 2
... 21 /PRNewswire/ Terumo Heart, Inc. today,announced the discharge of ... Assist System (LVAS). The patient was,discharged home on August ... after receiving the device., The patient is a ... heart failure for nearly 20 years. He is the ...
... have a study,that is falling behind with recruitment? Have ... media but still have not seen the,desired results? Perhaps ... to help,your sites navigate the world of media placements ... Argonauta Assist(TM) service," says Ms. Ann Kottcamp,President of Argonauta ...
Cached Medicine Technology:Discharge of First U.S. DuraHeart(TM) Patient 2Argonauta Assist(TM)ance: Argonauta Communications Strives to Enhance Site-Based Recruitment Efforts 2
(Date:3/28/2015)... 28, 2015 Pitching speed, player’s height, and ... shoulder and elbow injuries, according to new research released today ... ) Specialty Day. , “Our findings indicate that a 10 ... in likelihood of a history of injury, a 10 mile ... increase likelihood of a history of injury, and playing for ...
(Date:3/28/2015)... NV (PRWEB) March 28, 2015 Early ... patients with Type V AC joint injuries, according to ... presented today at the American Orthopaedic Society for Sports ... returned to duty faster when surgery was not performed. ... with 7 receiving surgical treatment and 17 receiving non-surgical ...
(Date:3/28/2015)... March 28, 2015 Aureus Medical ... staffing, including physical therapy jobs, has announced that ... Ohio Physical Therapy Association Annual Conference to be ... Downtown Hotel in Columbus, OH. , The ... and exhibits with products and services. , ...
(Date:3/28/2015)... ARDX will sponsor the 7th Annual Women’s Wellness ... Chesapeake Conference Center in Chesapeake, Virginia. Each year, ARDX ... women in the Hampton Roads region. The 2015 Women’s ... Women grow stronger through sharing their stories and learning ... the WWC™ theme is T-talk where we will share a ...
(Date:3/27/2015)... 27, 2015 The Monogamy Method ... experts Samantha Sanderson and Jason Rogers has just been ... media attention. The commotion surrounding the course's launch has ... to publish an in-depth review of the new program. ... men in their lives suddenly start pulling away or ...
Breaking Medicine News(10 mins):Health News:Researchers Highlight Shoulder and Elbow Injury Possibility in Youth Players 2Health News:For Type V AC Joint Injuries, Early Surgery May Not Be the Best Approach 2Health News:Healthcare Staffing Leader, Aureus Medical Group, to Exhibit at the Ohio Physical Therapy Association Annual Conference 2Health News:The Monogamy Method - Review Of Samantha Sanderson & Jason Rogers' Relationship Program Released 2
... study finds that people who receive higher disability ratings ... the long term than those who get lower ratings.// ... first to examine the relationship between Workers’ Compensation settlements ... which reinforces previous research showing ‘blacks receive less treatment ...
... suggests that patients who receive transfusions during heart bypass ... infections, and dying, after their operation. ,In ... medical mystery: why women bypass patients are more likely ... after surgery. Women are more likely to receive blood ...
... Kidney stones in children—considered all but a medical aberration ... a growing and disturbing trend that has pediatricians at ... sounding the alarm. ,While doctors have yet to ... behind it—better detection devices probably play some role—pediatricians agree ...
... strategy to combat malaria is abuzz, and the main action ... // ,The researchers from the National Institutes of Health ... mice, instigated them to produce antibodies against the parasite, Plasmodium ... of the mice, gain access into the mosquito’s body, through ...
... expressed their shock and disappointment on hearing the news ... //sentences on five Bulgarian nurses and one Palestinian doctor ... ,George Bush has expressed his "disappointment" to ... Bulgaria's attempts to strive for the release of the ...
... Muir Beach, CA, was living day-to-day, extremely ill, with ... dependent// on kidney dialysis. She needed a kidney transplant ... her doctors believed that a transplant was not possible ... specialized type of anti-rejection therapy pioneered at Cedars-Sinai Medical ...
Cached Medicine News:Health News:Is Workers’ Comp. Settlements for Back Pain Fair 2Health News:Blood Transfusions Raise Heart Patients’ Infection and Death Ris 2Health News:Blood Transfusions Raise Heart Patients’ Infection and Death Ris 3Health News:Kidney Stones Occurring More Often in Children 2Health News:Anti-rejection Therapy a Boon for Patients With "anti-donor" Antibody Levels 2Health News:Anti-rejection Therapy a Boon for Patients With "anti-donor" Antibody Levels 3Health News:Anti-rejection Therapy a Boon for Patients With "anti-donor" Antibody Levels 4
Irrigating Capsulorhexis Cystotome. Formed blunt tip, 25 g. Overall length 22 mm. 5/box....
Irrigating Cystotome, formed, 23 g., 12 mm curved tip. Overall length 14 mm. 5/box....
Retrobulbar Needle, 25 g. Atkinson style bevel. Overall length 38 mm. 5/box....
Peribulbar Needle, 23 g. Atkinson style bevel. Overall length 31 mm. 5/box....
Medicine Products: